TG6050 is an oncolytic virus derived from Transgene's Invir.IO® platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody, with the potential to trigger a powerful antitumor immune response.
P R E S S R E L E A S E Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered. | May 10, 2023
MyJournals.org - Science - Pharmaceuticals, Vol. 16, Pages 709: Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy (Pharmaceuticals)